Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- Pediatric gigantism due to ectopic growth hormone releasing hormone secretion from a metastatic bronchial neuroendocrine tumor.
- Extrarenal Papillary Renal Cell Carcinoma: A Unique Case With Bilateral Involvement of the Adrenal Glands.
- The elusive culprit: a renal neuroendocrine tumor unmasked by ectopic Cushing syndrome.
- Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.
- Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited-Resource Setting.
- Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609).
- Pediatric Pleomorphic Xanthoastrocytomas: A Multicenter Neuroradiologic and Clinical Correlation Study
- Primary angiosarcoma of the nasal septum: a rare case report and literature review
- 726 Soluble HVEM is associated with pathological complete response in triple-negative breast cancer
- 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
- 42 Integrated systemic and spatial profiling reveals vascular-immune determinants of response to dual PD-L1 and VEGF blockade in refractory melanoma
- 249 A genome-scale, in vivo transcription factor screen identifies a previously unrecognized factor that enhances CAR-T persistence and tumor control under high-dose rechallenge
- 179 Machine learning-based prediction of CAR-T cell therapy response in pediatric acute lymphoblastic leukemia patients using single-cell multi-omics features
- 270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
- 679 Novel 4-thiazolidinone derivative Les-4367 synergizes with trastuzumab and pertuzumab to suppress immune evasion markers in HER2-positive gastric cancer
- 334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy
- 484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer
- 208 Development of an integrated in vitro and in vivo platform for rapid evaluation of in vivo CAR-T therapies
- 427 Eomes sustains progenitor exhausted CD8 T-cell differentiation required for optimal response to immune checkpoint blockade in melanoma
- 931 A TCF7 phosphorylation checkpoint controls B7-H3 CAR-T cell persistence in solid tumors and brain metastases
- 482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC
- 137 Age-associated characteristics of the tumor microenvironment in patients with advanced basal cell carcinoma treated with anti-PD-1 therapy
- 559 Armoring logic-gated CAR T cells with a membrane-tethered IL-12 booster: initial data from the EVEREST-2 study of A2B543 in advanced solid tumors
- 257 Preclinical evaluation of in vivo CAR-T therapies using human PBMC and HSC reconstituted mouse models in Biocytogen
- 75 High-plex spatial profiling of cell–cell interactions directly in human FFPE tissue